DDInter493 DDInter1658
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Degarelix {u} (Compound) resembles {v} (Compound) Nafarelin
Degarelix {u} (Compound) resembles {v} (Compound) Cetrorelix
Degarelix {u} (Compound) treats {v} (Disease) prostate cancer
Degarelix {u} (Compound) binds {v} (Gene) GNRHR
Degarelix {u} (Compound) causes {v} (Side Effect) Urticaria
Degarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Degarelix (Compound) resembles Nafarelin (Compound)
Degarelix (Compound) resembles Cetrorelix (Compound)
Degarelix (Compound) treats prostate cancer (Disease)
Degarelix (Compound) binds GNRHR (Gene)
Degarelix (Compound) causes Urticaria (Side Effect)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Degarelix may lead to a major life threatening interaction when taken with Amiodarone
Degarelix may lead to a major life threatening interaction when taken with Ivabradine